

# PHARMACY POLICY STATEMENT

## North Carolina Marketplace

DRUG NAME

Olumiant (baricitinib)

Olumiant is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. It is also indicated for the treatment of adults with severe alopecia areata. Olumiant has a black box warning for serious infections, mortality, malignancy, major adverse cardiac events, and thrombosis.

Olumiant (baricitinib) will be considered for coverage when the following criteria are met:

### Rheumatoid Arthritis (RA)

For initial authorization:

1. Member is at least 18 years of age; AND
2. Olumiant is prescribed by or in consult with a rheumatologist; AND
3. Member has a documented diagnosis of moderately to severely active RA; AND
4. Member must have a trial and failure of, or intolerance to methotrexate for at least 3 months;  
Note: If methotrexate is contraindicated, one of the following conventional DMARDs must be trialed instead: leflunomide, sulfasalazine, or hydroxychloroquine; AND
5. Member has documentation of an inadequate response to at least two preferred biologic DMARDs including at least one tumor necrosis factor (TNF) antagonist therapies (see Appendix); AND
6. Member does not have any laboratory abnormalities indicating neutropenia (ANC <1000 cells/mm<sup>3</sup>), lymphopenia (ALC <500 cells/mm<sup>3</sup>), or anemia (hemoglobin < 8 g/dL); AND
7. Member has had a negative tuberculosis test within the past 12 months.
8. Dosage allowed/Quantity limit: 2 mg once daily. Quantity Limit: 30 tablets per 30 days.

If all the above requirements are met, the medication will be approved for 6 months.

For reauthorization :

## Alopecia Areata (AA)

12/28/2021	Transferred to new template. Added new reference. Changed initial approval duration to 6 months (was 12 months). Edited the terminology “non-biologic” DMARD to “conventional” DMARD. Changed from requiring 2 csDMARD to just 1.
06/27/2022	Added criteria for new indication of AA.
08/16/2023	AA: Removed attestation of significant psychological distress and trials of topical therapy or an oral corticosteroid.
09/27/2023	AA: added trials of topical therapy or an oral corticosteroid and trial of Litfulo

References:

1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; 2022.
2. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016;68(1):1-26.
3. Smolen JS, Landewé RBM, Bijlsma JWW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020;79(6):685-699.
4. Genovese MC, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. *N Engl J Med.* 2016 Mar 31;374(13):1243-52.
5. Taylor PC, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N Engl J Med.* 2017 Feb 16;376(7):652-662
6. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2021;73(7):1108-1123. doi:10.1002/art.41752
7. King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. *N Engl J Med.* 2022;386(18):1687-1699. doi:10.1056/NEJMoa2110343
8. Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol.* 2020;183(4):702-709. doi:10.1111/bjd.18883
9. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. *Br J Dermatol.* 2012;166(5):916-926. doi:10.1111/j.1365-2133.2012.10955.x
10. Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: An Australian expert consensus statement. *Australas J Dermatol.* 2019;60(2):163-170. doi:10.1111/ajd.12941
11. Rossi A, Muscianese M, Piraccini BM, et al. Italian Guidelines in diagnosis and treatment of alopecia areata. *G Ital Dermatol Venereol.* 2019;154(6):609-623. doi:10.23736/S0392-0488.19.06458-7
12. IPD Analytics. Accessed July 8, 2022.

Effective date: 01/01/2024

Revised date: 09/27/2023

Appendix: Preferred Biologic Products	
Approved for Rheumatoid Arthritis	<ul style="list-style-type: none"> <li>x Actemra (requires step through adalimumab)</li> <li>x Enbrel</li> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira</li> </ul>
Approved for Juvenile Idiopathic Arthritis	<ul style="list-style-type: none"> <li>x Actemra (requires step through Humira)</li> <li>x Enbrel</li> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira</li> </ul>
Approved for Ankylosing Spondylitis	<ul style="list-style-type: none"> <li>x Cosentyx</li> <li>x Enbrel</li> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira</li> <li>x Rinvoq</li> </ul>

Approved for Non-radiographic Axial	<ul style="list-style-type: none"> <li>x Cimzia</li> <li>x Cosentyx</li> </ul>
Approved for Atopic Dermatitis	<ul style="list-style-type: none"> <li>x Rinvoq</li> </ul>
Approved for Psoriatic Arthritis	<ul style="list-style-type: none"> <li>x Cosentyx</li> <li>x Enbrel</li> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira</li> <li>x Otezla</li> <li>x Skyrizi</li> <li>x Stelara</li> <li>x Tremfya</li> </ul>
Approved for Psoriasis	<ul style="list-style-type: none"> <li>x Cosentyx</li> <li>x Enbrel</li> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira</li> <li>x Otezla</li> <li>x Skyrizi</li> <li>x Stelara</li> <li>x Tremfya</li> </ul>
Approved for Crohn's Disease	<ul style="list-style-type: none"> <li>x Preferred adalimumab product - adalimumab-adaz, adalimumab-fk' €ODfk' €OD@À2w!6radaz,</li> </ul>